miRNA-223, on the other hand, has been found by researchers to directly target the inhibition of ABCG5/8 to reduce the occurrence of GSD, but whether it will inversely lead to an increased risk of AMI is not conclusive51. Here, ABCG5 is linked to disorder of glycogen metabolism.